Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
OREX [NASD]
Orexigen Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.82 Insider Own11.49% Shs Outstand116.33M Perf Week-0.56%
Market Cap615.39M Forward P/E- EPS next Y-0.27 Insider Trans54.07% Shs Float115.42M Perf Month-9.73%
Income-83.20M PEG- EPS next Q-0.09 Inst Own89.80% Short Float19.23% Perf Quarter-5.37%
Sales3.40M P/S181.00 EPS this Y37.00% Inst Trans-0.36% Short Ratio6.46 Perf Half Y-21.98%
Book/sh0.19 P/B27.84 EPS next Y-145.50% ROA-63.60% Target Price11.63 Perf Year-26.12%
Cash/sh1.33 P/C3.97 EPS next 5Y- ROE-246.20% 52W Range4.60 - 7.84 Perf YTD-6.04%
Dividend- P/FCF- EPS past 5Y21.90% ROI-63.30% 52W High-32.53% Beta2.40
Dividend %- Quick Ratio7.20 Sales past 5Y102.40% Gross Margin- 52W Low15.00% ATR0.23
Employees50 Current Ratio7.20 Sales Q/Q0.00% Oper. Margin- RSI (14)39.74 Volatility3.41% 4.26%
OptionableYes Debt/Eq3.88 EPS Q/Q-9.50% Profit Margin- Rel Volume0.51 Prev Close5.36
ShortableYes LT Debt/Eq3.88 EarningsAug 04 Payout- Avg Volume3.44M Price5.29
Recom1.60 SMA20-6.04% SMA50-9.75% SMA200-11.98% Volume1,761,866 Change-1.31%
10-Jan-14Initiated WallachBeth Buy $9
03-Oct-13Initiated Cowen Outperform $10
21-Sep-11Upgrade JMP Securities Mkt Perform → Mkt Outperform $5
01-Feb-11Downgrade JMP Securities Mkt Outperform → Mkt Perform
01-Feb-11Downgrade Canaccord Genuity Buy → Hold
03-Dec-10Downgrade Rodman & Renshaw Mkt Perform → Mkt Underperform
16-Jul-10Reiterated JMP Securities Mkt Outperform $16 → $13
16-Jul-10Downgrade Rodman & Renshaw Mkt Outperform → Mkt Perform
02-Feb-10Initiated Jefferies & Co Buy $12
24-Jun-09Initiated Rodman & Renshaw Mkt Outperform $14
13-Mar-09Reiterated Lazard Capital Mkts Buy $13 → $10
03-Apr-08Initiated Cowen & Co Outperform
06-Feb-08Initiated Lazard Capital Buy
04-Feb-08Reiterated Canaccord Adams Buy $29 → $32
03-Jan-08Initiated JP Morgan Overweight
03-Oct-07Upgrade JMP Securities Mkt Outperform → Strong Buy $26
07-Jun-07Initiated JP Morgan Overweight
06-Jun-07Initiated JMP Securities Mkt Outperform $26
21-Jul-14 09:46AM  Perilous Reversal Watch: Orexigen Therapeutics (OREX) at TheStreet
19-Jul-14 04:14PM  The Implications of Obesity as a Disability in Europe at Motley Fool
18-Jul-14 10:09AM  Trade-Ideas: Orexigen Therapeutics (OREX) Is Today's "Dead Cat Bounce" Stock at TheStreet +5.56%
05:47AM  Call buyers returning to Orexigen optionMONSTER
15-Jul-14 06:50PM  Arena Pharmaceuticals Inc. Still Down After CEO's Sale at Motley Fool
11-Jul-14 01:01PM  Arena Stock Holds On Expected Dip In Sales - Bottom May Be In at Seeking Alpha
06:14AM  Bull throws weight behind Orexigen optionMONSTER
10-Jul-14 11:54AM  14 Insanely Important Biotech/Drug Trading Catalysts for the Rest of 2014 at TheStreet
03-Jul-14 04:11PM  3 Stocks Even Volatility-Loving Nasdaq Investors Hate at Motley Fool
04:06PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Subm EDGAR Online
01-Jul-14 06:09PM  The Next Orphan Drug Multibagger and Future Obesity Champion? at Motley Fool
27-Jun-14 05:30PM  Are Investors Wrong About Orexigen Therapeutics? at Motley Fool
05:30PM  Are Investors Wrong About Orexigen Therapeutics?
05:01PM  3 Biotech Stocks with Catalysts Incoming: Spectrum, Orexigen, and Avanir at Motley Fool
05:01PM  3 Biotech Stocks with Catalysts Incoming: Spectrum, Orexigen, and Avanir
25-Jun-14 05:30PM  Are Investors Wrong About VIVUS? at Motley Fool
05:30PM  Are Investors Wrong About VIVUS?
24-Jun-14 06:20AM  How Bad Is This Delay for Orexigen Therapeutics, Inc? at Motley Fool
06:20AM  How Bad Is This Delay for Orexigen Therapeutics, Inc?
20-Jun-14 11:34AM  The Anti-Obesity Space Is Not As Simple As Some Think at Seeking Alpha
11:34AM  The Anti-Obesity Space Is Not As Simple As Some Think
03:19AM  Now Available: Shares in Zafgen, the Best Obesity Drugmaker to Date at Motley Fool
03:19AM  Now Available: Shares in Zafgen, the Best Obesity Drugmaker to Date
19-Jun-14 03:12PM  Why Zafgen Inc. Shares Roared Higher at Motley Fool
07:24AM  The Zacks Analyst Blog Highlights: Idenix, Achillion Pharmaceuticals, Nektar, Orexigen, Celgene, Alexion and Biogen Zacks
07:24AM  The Zacks Analyst Blog Highlights: Idenix, Achillion Pharmaceuticals, Nektar, Orexigen, Celgene, Alexion and Biogen
18-Jun-14 09:33AM  Biotech Stock Roundup: HCV Back in Focus - Idenix, Achillion Soar Zacks
09:33AM  Biotech Stock Roundup: HCV Back in Focus - Idenix, Achillion Soar
17-Jun-14 07:41AM  Orexigen (OREX) in Focus: Stock Moves 7.5% Higher Zacks
07:41AM  Orexigen (OREX) in Focus: Stock Moves 7.5% Higher
16-Jun-14 04:19PM  What Will It Take For Arena Stock To Rise? at Seeking Alpha +7.52%
04:19PM  What Will It Take For Arena Stock To Rise?
08:00AM  3 Stocks Crushed by the Market This Week at Motley Fool
08:00AM  3 Stocks Crushed by the Market This Week
15-Jun-14 11:20AM  This Week in Biotech: Actions Speak Louder Than Words at Motley Fool
11:20AM  This Week in Biotech: Actions Speak Louder Than Words
13-Jun-14 05:32PM  Is It Time to Buy Orexigen? at Motley Fool
05:32PM  Is It Time to Buy Orexigen?
02:56PM  Vivus Suit Preserves Exclusivity Of Qsymia - For Now at Seeking Alpha
02:56PM  Vivus Suit Preserves Exclusivity Of Qsymia - For Now
02:49PM  Arena's Belviq Sales Do More Than Recover at Seeking Alpha
08:30AM  Orexigen Therapeutics to Present at the Wells Fargo Securities 2014 Healthcare Conference PR Newswire
06:04AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
12-Jun-14 05:30PM  Orexigen Slumps as Obesity Drug Approval Delayed Zacks
01:19PM  Nasdaq stocks posting largest percentage decreases AP
06:50AM  Orexigen Therapeutics (OREX) in Focus: Stock Tumbles 14.7% Zacks
04:47AM  Cramer's Lightning Round - Trains Are On The Rails (6/11/14) at Seeking Alpha
11-Jun-14 08:34PM  Why Orexigen Therapeutics, United Natural Foods, and United Continental Holdings Tumbled Today at Motley Fool -14.68%
06:02PM  Nasdaq stocks posting largest percentage decreases AP
05:07PM  Why Orexigen Therapeutics Inc. Shares Were Throttled at Motley Fool
05:02PM  Orexigen Irony: No VIVUS Bounce at 24/7 Wall St.
02:11PM  Why Orexigen Therapeutics is Falling Today at Motley Fool
12:58PM  Orexigen falls on further FDA delays for diet pill AP
12:42PM  Dow breaks five-session win streak Hot Stock Minute
12:02PM  Why Don't Doctors Prescribe More Weight-Loss Drugs? at BusinessWeek
11:55AM  Orexigen Obesity Drug Decision Delayed By FDA at Investor's Business Daily
11:34AM  Down 18%: Is Orexigen a Bad News Buy? at Motley Fool
11:16AM  Biotech Stock Roundup: Biogen Hemophilia Drug Approved, Ariad & Halozyme Clinical Hold Lifted Zacks
11:03AM  Orexigen falls on further FDA delays for diet pill AP
10:07AM  Ahead of the Bell: Orexigen Therapeutics slips AP
10:07AM  Orexigen shares hit by FDA delay in obesity drug at CNBC
10:07AM  Why Orexigen Therapeutics (OREX) Stock Is Down Today at TheStreet
09:41AM  Orexigen Falls on Three-Month Extension of Weight-Loss Pill at Bloomberg
09:28AM  FDA Delays Decision On Orexigen Anti-Obesity Drug - What This Means To The Stock at Seeking Alpha
09:24AM  Orexigen (OREX) Enters Overbought Territory Zacks
09:12AM  Wednesdays Top Biotech Stories: Orexigen, Portola, and Regeneron at Motley Fool
08:21AM  Ahead of the Bell: Orexigen Therapeutics slips AP
08:00AM  Orexigen Therapeutics Inc Receives Three Month Extension of FDA NB32 Review Call scheduled for 8:00 am ET today CCBN
07:25AM  [$$] Orexigen Shares Drop as FDA Delays Approval at The Wall Street Journal
07:17AM  [$$] Orexigen Shares Drop as FDA Delays Approval at The Wall Street Journal
07:05AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Other Events EDGAR Online
06:48AM  FDA Delays Decision on Orexigen Obesity Pill by 3 Months at TheStreet
06:30AM  Orexigen Receives Three Month Extension of FDA NB32 Review PR Newswire
10-Jun-14 03:10PM  Orexigen's Date With Destiny at Motley Fool
01:22PM  Orexigen Investors Hope For FDA Approval at Seeking Alpha
09-Jun-14 05:22PM  Orexigen Could Be A Double-Edged Sword For Arena at Seeking Alpha
03:45PM  Orexigen's Upcoming Pipeline Catalyst Zacks
02:06PM  As Orexigen Faces FDA Will Weight Loss Landscape Change? at Motley Fool
01:39PM  [video] Expectations for new obesity drug at CNBC
12:45PM  Third time's a charm for Orexigen's obesity drug? at CNBC
12:45PM  Orexigen may give diet pill market the jolt it needs at CNBC
12:45PM  Obesity game-changer? Why this time it's different at CNBC
12:45PM  Obesity game changer? Why this time it's different at CNBC
12:43PM  Orexigen: 'Goldilocks' Obesity Pill Awaits FDA Approval Decision Wednesday at TheStreet
06-Jun-14 01:15PM  Arena Pharmaceuticals: Strong Sell On Multiple Red Flags at Seeking Alpha
11:58AM  Orexigen To Rise On Very Likely FDA Nod June 11th at Seeking Alpha
05-Jun-14 08:24PM  Don't Hold Your Breath Waiting for a VIVUS Inc. Buyout at Motley Fool
04-Jun-14 01:45PM  3 Stocks to Get on Your Watchlist at Motley Fool
02-Jun-14 08:30AM  The IBB Likely To Move Higher Along With These Biotechs With Catalysts Upcoming at Seeking Alpha
08:10AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Other Events EDGAR Online
08:00AM  Orexigen Announces June 11, 2014 PDUFA Action Date for NB32 PR Newswire
30-May-14 05:06PM  Arena vs Vivus: Which Obesity Stock is a Buy? at Motley Fool
04:46PM  Belviq Sales Climb - Are Ads Effective? at Seeking Alpha
29-May-14 06:35PM  The Beginning of the (Merciful) End for VIVUS, Inc Shareholders? at Motley Fool
05:44PM  Here's What This Infamous Money-Manager Has Sold at Motley Fool
08:10AM  Orexigen (OREX) in Focus: Stock Moves 6.1% Higher Zacks
28-May-14 05:25PM  Why Ballard Power Systems, PTC Therapeutics, and VIVUS Are Today's 3 Best Stocks at Motley Fool +6.10%
04:56PM  Aspen Investment Said To Be Offering $640 Million For Vivus at Seeking Alpha
01:52PM  Why VIVUS Inc. Shares Spiked Higher at Motley Fool
08:30AM  Orexigen's Weight Loss Drug Will Be Approved Soon And Will Lead Market - Here Is Why at Seeking Alpha
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its product candidates include NB32, which has completed Phase III clinical trials and is being studied in a cardiovascular outcomes trial; and Empatic that has completed Phase II clinical trials. Orexigen Therapeutics, Inc. has collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize NB32 in the United States, Canada, and Mexico. The company was founded in 2002 and is headquartered in La Jolla, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DOVEY BRIAN HDirectorApr 22Option Exercise0.004,691,4704,6917,580,065Apr 23 05:15 PM
Hagan Joseph PChief Business OfficerJul 31Option Exercise1.6612,00019,92012,000Aug 02 07:34 PM
Hagan Joseph PChief Business OfficerJul 31Sale7.8012,00093,6000Aug 02 07:34 PM
Booth Mark DChief Commercial OfficerJul 26Option Exercise1.6664,767107,51364,767Jul 29 07:50 PM
Hagan Joseph PChief Business OfficerJul 26Option Exercise1.6610,00016,60010,000Jul 29 07:49 PM
Hagan Joseph PChief Business OfficerJul 26Sale7.4010,00074,0000Jul 29 07:49 PM
Booth Mark DChief Commercial OfficerJul 26Sale7.5564,767489,0830Jul 29 07:50 PM